Hypocholesterolaemic agents

A method for inhibiting the intestinal lipid transport of an animal or human being in need thereof, which comprises orally administering to such animal or human being an effective amount of a hypocholesterolaemic agent which is selected from the group consisting of (A) a polyoxybutylene-polyoxyethylene block copolymer, said block copolymer being a cogeneric mixture of conjugated polyoxybutylene-polyoxyethylene compounds containing in their structure oxybutylene groups, oxyethylene groups and an organic radical derived from a water-soluble organic compound containing a plurality of reactive hydrogen atoms, the compounds being characterized in that all the oxybutylene groups are present in polyoxybutylene chains that are attached to the organic radical at the site of a reactive hydrogen atom thereby principally constituting a polyoxybutylene polymer;

• the oxyethylene groups being attached to the polyoxybutylene polymer in polyoxyethylene chains;
• the approximate average molecular weight of the polyoxybutylene polymers in the mixture being between 600 and 4000, as determined by hydroxyl number, and the oxyethylene groups present constituting about 5 to about 50 percent by weight of the compound, and (B) a compound of the formula:
• ##STR3## wherein R and R.sup.1 are H or the residue of an aliphatic, cycloaliphatic, or aromatic acid containing from 2 to 12 carbon atoms with the proviso that only one of R and R.sup.1 may be H and m+m' and n are integers such that the approximate average molecular weight of (C.sub.4 H.sub.8 O).sub.n, representing a polyoxybutylene hydrophobe is between 600 and 4000 and the content of (C.sub.2 H.sub.4 O).sub.m+m', representing oxyethylene groups constitute about 5 to about 50 percent by weight of the compound.